SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-054637
Filing Date
2023-10-23
Accepted
2023-10-23 16:30:18
Documents
14
Period of Report
2023-10-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acst-20231018.htm   iXBRL 8-K 56869
2 EX-10.1 acst-ex10_1.htm EX-10.1 40841
3 EX-99.1 acst-ex99_1.htm EX-99.1 22556
  Complete submission text file 0000950170-23-054637.txt   250671

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acst-20231018_lab.xml EX-101.LAB 13360
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acst-20231018_pre.xml EX-101.PRE 9851
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acst-20231018.xsd EX-101.SCH 2481
8 EXTRACTED XBRL INSTANCE DOCUMENT acst-20231018_htm.xml XML 4705
Mailing Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5
Business Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5 450-686-4555
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 231340279
SIC: 2834 Pharmaceutical Preparations